Over the past decade, immune checkpoint inhibitors (ICIs) have emerged as a revolutionary
cancer treatment modality, offering long-lasting responses and survival benefits for a …

The tumor microenvironment (TME) is essential for immune escape by tumor cells. It plays
essential roles in tumor development and metastasis. The clinical outcomes of tumors are …

Cuproptosis is a novel copper ion-dependent cell death type being regulated in cells, and
this is quite different from the common cell death patterns such as apoptosis, pyroptosis …

Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1)-blockade
immunotherapies have limited efficacy in the treatment of bladder cancer. Here, we show …

Immune checkpoint blockade (ICB) has rapidly transformed the treatment paradigm for
various cancer types. Multiple single or combinations of ICB treatments have been approved …

Chemoimmunotherapy has shown great potential to activate an immune response, but the
immunosuppressive microenvironment associated with T cell exhaustion remains a …

Purpose: TIGIT (T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-
based inhibitory motif domain) is a co-inhibitory receptor of T-cell and natural killer cell …

Pancreatic ductal adenocarcinoma (PDAC) has a poor clinical outlook. Responses to
immune checkpoint blockade are suboptimal and a much more detailed understanding of …

Background Although cancer immunotherapy is one of the most effective advanced-stage
cancer therapies, no clinically approved cancer immunotherapies currently exist for …

Background While improvements in immunoradiotherapy have significantly improved
outcomes for cancer patients, this treatment approach has nevertheless proven ineffective at …